Viking Therapeutics Inc (VKTX)
52.62
+0.99
(+1.92%)
USD |
NASDAQ |
Nov 22, 16:00
52.74
+0.12
(+0.23%)
After-Hours: 16:39
Viking Therapeutics Research and Development Expense (Quarterly): 22.78M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 22.78M |
| June 30, 2024 | 23.77M |
| March 31, 2024 | 24.10M |
| December 31, 2023 | 20.50M |
| September 30, 2023 | 18.38M |
| June 30, 2023 | 13.92M |
| March 31, 2023 | 11.01M |
| December 31, 2022 | 16.18M |
| September 30, 2022 | 11.96M |
| June 30, 2022 | 13.54M |
| March 31, 2022 | 12.56M |
| December 31, 2021 | 9.847M |
| September 30, 2021 | 10.80M |
| June 30, 2021 | 12.80M |
| March 31, 2021 | 11.54M |
| December 31, 2020 | 9.049M |
| September 30, 2020 | 7.116M |
| June 30, 2020 | 7.78M |
| March 31, 2020 | 7.987M |
| December 31, 2019 | 6.451M |
| September 30, 2019 | 5.279M |
| June 30, 2019 | 7.333M |
| March 31, 2019 | 4.496M |
| Date | Value |
|---|---|
| December 31, 2018 | 5.089M |
| September 30, 2018 | 5.687M |
| June 30, 2018 | 5.221M |
| March 31, 2018 | 3.043M |
| December 31, 2017 | 3.033M |
| September 30, 2017 | 3.465M |
| June 30, 2017 | 3.716M |
| March 31, 2017 | 3.528M |
| December 31, 2016 | 2.648M |
| September 30, 2016 | 2.105M |
| June 30, 2016 | 2.371M |
| March 31, 2016 | 1.877M |
| December 31, 2015 | 3.219M |
| September 30, 2015 | 2.508M |
| June 30, 2015 | 1.101M |
| March 31, 2015 | 0.139M |
| December 31, 2014 | 0.1428M |
| September 30, 2014 | 0.7886M |
| June 30, 2014 | 21.24M |
| March 31, 2014 | 0.05M |
| June 30, 2013 | 0.0033M |
| March 31, 2013 | 0.0006M |
| December 31, 2012 | 0.0689M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.451M
Minimum
Dec 2019
24.10M
Maximum
Mar 2024
13.60M
Average
12.26M
Median
Research and Development Expense (Quarterly) Benchmarks
| Amgen Inc | 1.45B |
| Eli Lilly and Co | 2.734B |
| Pfizer Inc | 2.598B |
| Structure Therapeutics Inc | 32.60M |
| Altimmune Inc | 19.80M |